Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chen, Huan ^a   Liu, Kai Yan ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Chen, Yu Hong ^a   Zhao, Xiang Yu ^a   Han, Wei ^a   Zhang, Xiao Hui ^a   Wang, Yu ^a   Zhang, Yuan Yuan ^a   Qin, Ya Zhen ^a   Liu, Yan Rong ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic cell transplantation; Imatinib; Minimal residual disease; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER PROGNOSIS; CHILD; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861925876     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-29     Document Type: Article

References (31)

1. Philadelphia chromosome-positive acute lymphoblastic leukemia. Rdich JP, Hematol Oncol Clin North Am 2001 15 21 36 10.1016/S0889-8588(05)70198-2 11258387 (Pubitemid 32201866)
2. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, et al. Blood 1997 90 1410 1414 9269758 (Pubitemid 27355413)
3. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors:a 20year experience with the fractionted total body irradiation-etoposide regimen. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, et al. Blood 2008 112 903 909 10.1182/blood-2008-03-143115 18519812
4. Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Xu LP, Huang XJ, Liu KY, Chen Huan, Liu DH, Zhang YC, et al. Beijing Da Xue Xue Bao 2005 37 3 231 235 Chinese 15968308
5. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Wei G, Rafiyath S, Liu DL, J Hematol Oncol 2010 3 47 10.1186/1756-8722-3-47 21108851
6. Update of recent studies in chronic myeloid leukemia. Karen Seiter, J Hematol Oncol 2009 2 Suppl 1 2 26 June 2009 10.1186/1756-8722-2-S1-A2
7. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. Blood 2005 105 3449 3457 10.1182/blood-2004-09-3785 15657178 (Pubitemid 40628185)
8. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Blood 2007 109 1408 1413 10.1182/blood-2006-03-011908 17062730 (Pubitemid 46239571)
9. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. J Clin Oncol 2006 24 460 466 10.1200/JCO.2005.03.2177 16344315 (Pubitemid 46630465)
10. Detection of bcr-abl transcripts in Phyladelphia chromosome-positive acute lymphoblastic leukemia after bone marrow transplantation. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, et al. Blood 1997 97 2602 2609 (Pubitemid 27143311)
11. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Brug G, Scheuring UJ, et al. Blood 2005 106 458 463 10.1182/blood-2004-05-1746 15817679 (Pubitemid 40981238)
12. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Stirewalt DL, Guthrie KA, Beppu L, Bryant EM, Doney K, Gooley T, et al. Biol Blood Marrow Transplant 2003 9 206 212 10.1016/S1083-8791(03)70011-1 12652472
13. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Carpenter PA, Snyder DS, Flower ME, Sanders JE, Gooley TA, Martin PJ, et al. Blood 2007 109 2791 2793 17119111 (Pubitemid 46482072)
14. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Bone Marrow Transplant 2006 38 291 297 10.1038/sj.bmt.1705445 16883312 (Pubitemid 44203779)
15. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. Huan XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, et al. J Clin Immunol 2008 28 4 390 397 10.1007/s10875-008-9193-4 18347959
16. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang y, et al. Int J Lab Hematol 2008 30 317 323 10.1111/j.1751-553X.2007.00962.x 18665830
17. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using real-time quantitative reverse- transcriptase polymerase chain reaction (RQPCR)a Europe against cancer program. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Leukemia 2003 17 2474 2486 10.1038/sj.leu.2403136 14562124 (Pubitemid 38072587)
18. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemiaa Europe Against Cancer program. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Leukemia 2003 17 2318 2357 10.1038/sj.leu.2403135 14562125 (Pubitemid 38072573)
19. Administration of imatinib in first 90 days after allogeneic hematopoistic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Shi HX, et al. Chin Med J 2011 124 2 246 252 21362375
20. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DL, Waqner JE, et al. Bone Marrow Transplant 2009 43 2 107 113 10.1038/bmt.2008.296 18776928
21. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Childrens Oncology Group Study. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. J Clin Oncol 2009 27 5175 5181 10.1200/JCO.2008.21.2514 19805687
22. Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Childrens Oncology Group (COG) Study AALL0031. Schultz KR, Bowman WP, Slayton W, Aledo A, Devidas M, Sather H, et al. Blood 2007 110 4
23. Imatinib mesylate administration in the first 100day after stem cell transplantation. Anderlini P, Sheth S, Hicks K, Ippolili C, Giratt S, Champlin RE, et al. Biol Blood Marrow Transplant 2004 10 883 884 10.1016/j.bbmt.2004.09. 004 15570257 (Pubitemid 39625310)
24. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Ribera JM, Oriol A, Gonzalez M, Brunet S, Esteve J, Del Potro E, et al. Haematologica 2010 95 1 87 95 10.3324/haematol.2009.011221 19797728
25. Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)[abstract]. Blood. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, (ASH Annual Meeting Abstracts) 2011 118 21 614
26. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, et al. Cancer 2009 115 561 570 10.1002/cncr.24026 19117346
27. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Pane F, Cimino G, Izzo B, Canera A, Quintarelli C, Picardi M, et al. Leukemia 2005 19 628 635 15744351 (Pubitemid 40521168)
28. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, et al. Blood 2005 106 2 458 463 10.1182/blood-2004-05-1746 15817679 (Pubitemid 40981238)
29. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeqer N, et al. J Clin Oncol 2004 22 2816 2825 10.1200/JCO.2004.07.130 15254049 (Pubitemid 41079899)
30. Allogeneic hematopoietic stem cell transplabtationfor childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: A study of the Spanish Working Party for Blood and Marrow Transplantation in Children(Getmon). Munoz A, Diaz-Heredia C, Diaz MA, et al. Pediatr Hematol Oncol 2008 25 4 245 259 10.1080/08880010802016557 18484470 (Pubitemid 351874083)
31. Allogeneic hematopoietic cell transplantation for treatment of pediatric Philadelphia chromosome-positive acute lymphiblastic leukemia(ALL). Burke MJ, Cao Q, Trotz B, Weigel BJ, Kumar A, Smith A, et al. Pediatr Blood Cancer 2009 53 1289 1294 10.1002/pbc.22263 19731318